

DEPARTMENT OF HEALTH & HUMAN SERVICES
Centers for Medicare & Medicaid Services
150 S. Independence Mall West
Suite 216, The Public Ledger Building
Philadelphia, Pennsylvania 19106-3499



Region III/Division of Medicaid and Children's Health Operations

SWIFT #032720134008

APR 30 2013

Beverly Mackereth
Acting Secretary of Public Welfare
Department of Public Welfare
Room 333, Health & Welfare Building
P.O. Box 2675
Harrisburg, Pennsylvania 17105-2675


Dear Acting Secretary Mackereth:

We are pleased to inform you of the approval of Pennsylvania State Plan Amendment (SPA) 13-001 which proposes to exclude from coverage benzodiazepines for all conditions and barbiturates for the treatment of epilepsy, cancer and chronic mental health disorders for full benefit dual eligibles as Medicare Part D will provide this coverage.

The effective date of this amendment is January 1, 2013. This SPA was approved by the CMS Pharmacy Team on April 19, 2013. You should have received a letter from Larry Reed, Director of the Division of Pharmacy.

Enclosed are copies of the approved SPA pages and the signed CMS-179 form.

If you have any questions, you may contact Mary McKeon at (215) 861-4181.

Sincerely,

Francis T. McCullough
Associate Regional Administrator

Enclosures

cc: Daniel Sorge, DPW, Bureau of Policy, Analysis and Planning
Jessica Walker, Division of Pharmacy, CMCS

DEPARTMENT OF HEALTH & HUMAN SERVICES
Centers for Medicare & Medicaid Services
7500 Security Boulevard, Mail Stop S2-14-26
Baltimore, Maryland 21244-1850



Disabled & Elderly Health Programs Group

April 19, 2013

Beverly D. Mackereth, Acting Secretary
Commonwealth of Pennsylvania
Department of Public Welfare
Office of Medical Assistance Programs
Bureau of Policy, Analysis and Planning
P.O. Box 8046
Harrisburg, PA 17105

Dear Ms. Mackereth:

We have reviewed Pennsylvania's State Plan Amendment (SPA) 13-001, received in the Philadelphia Regional Office on March 22, 2013. This amendment proposes to exclude from coverage benzodiazepines for all conditions and barbiturates for the treatment of epilepsy, cancer and chronic mental health disorders for full benefit dual eligibles as Medicare Part D will provide this coverage.

Based on the information provided, we are pleased to inform you that SPA 13-001 is approved with an effective date of January 1, 2013. A copy of the signed CMS-179 form, as well as the pages approved for incorporation into the Pennsylvania state plan will be forwarded by the Philadelphia Regional Office.

If you have any questions regarding this amendment, please contact Jessica Walker at (410) 786-2457.

Sincerely,

/s/

Larry Reed
Director
Division of Pharmacy

cc: Francis McCullough, ARA, Philadelphia Regional Office
Mary McKeon Stosuy, Philadelphia Regional Office